Q3 Earnings Forecast for Korro Bio Issued By HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – Research analysts at HC Wainwright lowered their Q3 2025 earnings estimates for Korro Bio in a report released on Wednesday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.43) for the quarter, down from their previous estimate of ($1.88). HC Wainwright currently has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2025 earnings at ($2.26) EPS, FY2025 earnings at ($9.93) EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.28) EPS, Q3 2026 earnings at ($2.34) EPS, Q4 2026 earnings at ($2.39) EPS and FY2026 earnings at ($9.23) EPS.

Several other research firms have also commented on KRRO. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of Korro Bio in a report on Wednesday. Cantor Fitzgerald upgraded shares of Korro Bio to a “strong-buy” rating in a report on Tuesday, April 29th. Oppenheimer cut their price target on shares of Korro Bio from $155.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Finally, Raymond James Financial cut their price target on shares of Korro Bio from $153.00 to $147.00 and set a “strong-buy” rating on the stock in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Korro Bio currently has an average rating of “Buy” and an average target price of $86.83.

Korro Bio Stock Performance

KRRO opened at $20.26 on Friday. Korro Bio has a 1 year low of $10.29 and a 1 year high of $98.00. The company’s 50 day simple moving average is $14.32 and its 200 day simple moving average is $18.12. The stock has a market capitalization of $190.24 million, a PE ratio of -2.08 and a beta of 2.51.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Tuesday, August 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $0.41 million.

Institutional Trading of Korro Bio

A number of hedge funds have recently made changes to their positions in KRRO. Wells Fargo & Company MN raised its stake in shares of Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock valued at $129,000 after purchasing an additional 831 shares during the period. Bank of Montreal Can purchased a new stake in shares of Korro Bio during the fourth quarter valued at approximately $217,000. Legal & General Group Plc raised its stake in shares of Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock valued at $165,000 after purchasing an additional 3,759 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Korro Bio during the fourth quarter valued at approximately $394,000. Finally, Barclays PLC purchased a new stake in shares of Korro Bio during the fourth quarter valued at approximately $395,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).